Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) and IN8bio (NASDAQ:INAB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
Profitability
This table compares Cardiol Therapeutics and IN8bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiol Therapeutics | N/A | -118.65% | -85.28% |
| IN8bio | N/A | -173.12% | -118.40% |
Volatility and Risk
Cardiol Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, IN8bio has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiol Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
| IN8bio | 0 | 0 | 2 | 0 | 3.00 |
Cardiol Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 353.37%. IN8bio has a consensus target price of $10.00, indicating a potential upside of 2,896.70%. Given IN8bio’s higher probable upside, analysts plainly believe IN8bio is more favorable than Cardiol Therapeutics.
Institutional and Insider Ownership
12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 15.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Cardiol Therapeutics and IN8bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiol Therapeutics | $60,000.00 | 2,570.12 | -$20.84 million | ($0.33) | -5.85 |
| IN8bio | N/A | N/A | -$30.01 million | ($0.83) | -0.40 |
Cardiol Therapeutics has higher revenue and earnings than IN8bio. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
Summary
Cardiol Therapeutics beats IN8bio on 9 of the 12 factors compared between the two stocks.
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
About IN8bio
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
